Dilorio Richard
Known title: President & CEOCIK: 0001706994
Dilorio Richard's purchase track record
Dilorio Richard has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/21/2023 | INFU | $23K | +32.5% | +31.0% | +11.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INFU | ▲ Buy | Option Exercise | 40,909 | $0 | 5/17/2025 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 19,509 | $120K | 5/17/2025 | View on chart |
| INFU | ▲ Buy | Option Exercise | 25,000 | $65K | 3/7/2025 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 17,976 | $111K | 3/7/2025 | View on chart |
| INFU | ▼ Sell | Open Market | 5,398 | $48K | 11/27/2024 | View on chart |
| INFU | ▼ Sell | Open Market | 14,602 | $130K | 11/26/2024 | View on chart |
| INFU | ▼ Sell | Open Market | 20,000 | $186K | 11/25/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 50,000 | $135K | 6/26/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 34,347 | $235K | 6/26/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 14,103 | $0 | 5/18/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 6,819 | $44K | 5/18/2024 | View on chart |
| INFU | ▲ Buy | Grant | 11,659 | $0 | 5/17/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 5,639 | $36K | 5/17/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 200,000 | $636K | 8/21/2023 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 109,350 | $1.2M | 8/21/2023 | View on chart |
| INFU | ▲ Buy | Open Market | 3,000 | $23K | 3/21/2023 | View on chart |
| INFU | ▲ Buy | Option Exercise | 166,332 | $333K | 11/14/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 95,024 | $828K | 11/14/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 4,435 | $35K | 8/24/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 6,653 | $56K | 5/20/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,127 | $27K | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Grant | 15,000 | $0 | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Grant | 7,050 | $0 | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 2,821 | $0 | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,252 | $11K | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 4,322 | $37K | 5/18/2022 | View on chart |
| INFU | ▲ Buy | Grant | 9,744 | $0 | 5/18/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 33,519 | $67K | 1/24/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 33,519 | $517K | 1/24/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 9,064 | $18K | 1/21/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 9,064 | $141K | 1/21/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 149 | $298 | 1/21/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 149 | $2K | 1/21/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 15,936 | $32K | 1/20/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 15,936 | $255K | 1/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.